Drug-Drug Interaction
Saturday, 14 March 2015
azelastine and ivacaftor interaction
azelastine increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Monitor when coadministered with weak CYP3A4 inhibitors
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment